Trials / Completed
CompletedNCT04754100
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
A Phase 1, Open-Label Study of the Safety, Tolerability, and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) in Subjects With Relapsed/Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- MiNK Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | agenT-797 | agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo. |
Timeline
- Start date
- 2021-03-29
- Primary completion
- 2023-01-13
- Completion
- 2023-05-31
- First posted
- 2021-02-15
- Last updated
- 2023-06-06
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04754100. Inclusion in this directory is not an endorsement.